By Kevin E. Noonan — The metes and bounds of how courts should consider indefiniteness under 35 U.S.C. § 112(b) were addressed most recently by the Supreme Court in Nautilus, Inc. v. Biosig Instruments, Inc., 572 U.S. 898 (2014). Regardless, however, of the Court’s attempts to properly construe this portion of the Patent Statute (and the Federal Circuit’s attempts to comply with those rubrics), the Federal Circuit’s recent decision in Vascular Solutions LLC v. Medtronic, Inc. illustrates once again that in patent law very little is simple or straightforward. And as set forth below, the Court’s decision has led to…



Source link

Leave a Comment

Your email address will not be published. Required fields are marked *